AbbVie CEO Upbeat On Skyrizi Commercialization, Raises Financial Guidance
AbbVie’s product pipeline may be delivering just in time to alleviate concerns about loss of exclusivity on its best-selling product, Humira.
You may also be interested in...
While it works on merging with Allergan, AbbVie is tracking biosimilar sales erosion to Humira, the promising launch of Skyrizi and the growth of Imbruvica and Venclexta. It is terminating a Phase II study of a tau-targeting antibody and worried about aspects of the Senate drug pricing bill.
AbbVie could be looking at near-simultaneous launches for Skyrizi on both sides of the Atlantic after the psoriasis drug – a key future growth driver – got a positive opinion from Europe's regulators some two months before the FDA is due to give its verdict on the interleukin-23 inhibitor.
Decreasing Humira’s ex-US sales guidance for the second time in three months caught significant attention, as AbbVie now expects 30% revenue erosion for its top-seller outside its home market.